Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 12/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.31 |
| ▸ | CALCR | P30988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583936 | 0.99 | CALCRL (0.37) | CALCRLGRIN2BGRIN2COPRM1OPRL1 | |
| SCHEMBL981287 | 0.98 | CALCRL (0.38) | CALCRLGRIN2BGRIN2COPRM1OPRL1 | |
| Lithium Ion SCHEMBL977109 | 0.90 | CALCRL (0.38) | CALCRLGRIN2BGRIN2COPRM1OPRL1 | |
| SCHEMBL978530 | 0.89 | CALCRL (0.36) | CALCRLGRIN2BGRIN2COPRM1OPRL1 | |
| SCHEMBL977107 | 0.86 | CALCRL (0.36) | CALCRLGRIN2BGRIN2COPRM1OPRL1 | |
| SCHEMBL12921080 | 0.86 | CALCRL (0.37) | CALCRLGRIN2BGRIN2COPRM1OPRL1 | |
| SCHEMBL979198 | 0.85 | CALCRL (0.38) | CALCRLGRIN2BGRIN2COPRM1OPRL1 | |
| SCHEMBL1274395 | 0.77 | GRIN2B (0.35) | GRIN2BGRIN2C | |
| SCHEMBL6344971 | 0.77 | GRIN2B (0.35) | GRIN2BGRIN2C | |
| SCHEMBL1274396 | 0.77 | GRIN2B (0.35) | GRIN2BGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893079-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20110021516-A1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021516-A1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | CCKAR, CALCRL, CCKBR | CALCRL 2/4885GRIN2B 300/4885GRIN2C 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.